Sargramostim in acute radiation syndrome

References

• DiCarlo AL, Maher C, Hick JL, et al. Radiation injury after a nuclear detonation: medical consequences and the need for scarce resources allocation. Disaster Med Public Health Prep. 2011;5(1):S32–44.
   PubMedGoogle Scholar
• Dörr H, Meineke V. Acute radiation syndrome caused by accidental radiation exposure - therapeutic principles. BMC Med. 2011;25(9):126.
   Google Scholar
• Weinstock DM, C C Jr, Bader JL, et al. Confer DL. Radiologic and nuclear events: contingency planning for hematologists/oncologists. Blood. 2008;15(12):5440–5445.
   Google Scholar
• Dainiak N, Waselenko JK, Armitage JO, et al. The hematologist and radiation casualties. Hematology Am Soc Hematol Educ Program. 2003;2003(1):473–496.
   Google Scholar
• Dainiak N, Ricks RC. The evolving role of haematopoietic cell transplantation in radiation injury: potentials and limitations. BJR Suppl. 2005;27(1):169–174
   Google Scholar
• Gale RP, Armitage JO. Are we prepared for nuclear terrorism? N Engl J Med. 2018;378(13):1246–1254. 2449-2450.
   PubMed Web of Science ®Google Scholar
• Second General Accounting Office Report on Sealed Radioactive Sources. General Accounting Office; 2003 Jun 16.
   Google Scholar
• Turai I, Veress K, Günalp B, et al. Major radiation exposure. N Engl J Med. 2002;347:944–947. author reply 944-7.
   PubMedGoogle Scholar
• Turai I, Veress K. Radiation accidents: occurrence, types, consequences, medical management, and the lessons to be learned. Central Eur J Occupational Environ Med. 2001;7:3–14.
   Google Scholar
• Obrador E, Salvador-Palmer R, Villaescusa JI, et al. Nuclear and radiological emergencies: biological effects, countermeasures and biodosimetry. Antioxidants (Basel). 2022;11(6):1098.
   PubMedGoogle Scholar
• DiCarlo AL, Horta ZP, Aldrich JT, et al. Use of growth factors and other cytokines for treatment of injuries during a radiation public health emergency. Radiat Res. 2019;192(1):99–120.
   PubMed Web of Science ®Google Scholar
• Stenke L, Hedman C, Lagergren Lindberg M, et al. The acute radiation syndrome-need for updated medical guidelines. J Radiol Prot. 2022;42(1):014004.
   Web of Science ®Google Scholar
• Gale RP, Armitage JO. Use of molecularly-cloned haematopoietic growth factors in persons exposed to acute high-dose, high-dose rate whole-body ionizing radiations. Blood Rev. 2021;45:100690.
   PubMed Web of Science ®Google Scholar
• Strategic National Stockpile Radiation Working Group, Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med. 2004;140(12):1037–1051.
   PubMed Web of Science ®Google Scholar
• Hall EJ, Giaccia AJ. Radiobiology for the radiologist. 7th ed. Lippincott, Williams, Wilkins, Philadelphia: PA;2012.
   Google Scholar
• Fliedner TM, Chao NJ, Bader JL, et al. Stem cells, multiorgan failure in radiation emergency medical preparedness: a U.S./European Consultation Workshop. Stem Cells. 2009;27(5):1205–1211.
   PubMed Web of Science ®Google Scholar
• Hill RP. Radiation effects on the respiratory system. Br J Radiol. 2005;78(Supplement 27,1):75–81.
   PubMedGoogle Scholar
• Gourmelon P, Marquette C, Agay D, et al. Involvement of the central nervous system in radiation-induced multi-organ dysfunction and/or failure. Br J Radiol. 2005;78(Supplement 27, 1):62–68.
   PubMedGoogle Scholar
• Sher N, Ofir R. Placenta-derived adherent stromal cell therapy for hematopoietic disorders: a case study of PLX-R18. Cell Transplant. 2018;27(1):140–150.
   PubMed Web of Science ®Google Scholar
• Singh VK, Garcia M, Seed TM. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status. Int J Radiat Biol. 2017;93(9):870–884. .
   PubMed Web of Science ®Google Scholar
• Leukine® (sargramostim). Full Prescribing Information. Partner Therapeutics, Inc; Lexington: MA: 2022. Available from: https://www.leukine.com/wp-content/uploads/2022/06/FPI-0010_Leukine-Prescribing-Information-May-2022.pdf ( Cited 5/19/22)
   Google Scholar
• Neupogen® (filgrastim). Full Prescribing Information. Amgen Inc.; Thousand Oaks: CA: 2021. Available from: (Cited May/19/2022https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/neupogen/neupogen_pi_hcp_english.pdf
   Google Scholar
• Neulasta® (pegfilgrastim). Full Prescribing Information. Amgen Inc.; Thousand Oaks: CA: 2021. Available from: https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/neulasta/neulasta_pi_hcp_english.pdf
   Google Scholar
• Farese AM, MacVittie TJ. Filgrastim for the treatment of hematopoietic acute radiation syndrome. Drugs Today (Barc). 2015;51:537–548.
   PubMed Web of Science ®Google Scholar
• Singh VK, Seed TM. An update on sargramostim for treatment of acute radiation syndrome. Drugs Today (Barc). 2018;54(11):679–693.
   PubMed Web of Science ®Google Scholar
• Hercus TR, Thomas D, Guthridge MA, et al. The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood. 2009;114(7):1289–1298.
   PubMed Web of Science ®Google Scholar
• Yu JM, Meng ZY, Dou GF. Recent advances in research on granulocyte colony-stimulating factor–review. In: Zhongguo shi yan xue ye xue za zhi. 2008; Vol. 16. Chinese: Electronic Magazines Co., Ltd.;p. 452–456.
   Google Scholar
• Singh VK, Newman VL, Seed TM. Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): a review. Cytokine. 2015;71(1):22–37.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Ragsdale CE, Gale RP, et al. Sargramostim (rhu GM-CSF) as cancer therapy (systematic review) and an Immunomodulator. A drug before Its time? Front Immunol. 2021;12:706186.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Gale RP. G-CSF and GM-CSF are different. which one is better for COVID-19? Acta Haematol. 2021;144(4):355–359.
   PubMed Web of Science ®Google Scholar
• Metcalf D. The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood. 1986;67(2):257–267.
   PubMed Web of Science ®Google Scholar
• Park LS, Friend D, Gillis S, et al. Characterization of the cell surface receptor for human granulocyte/macrophage colony-stimulating factor. J Exp Med. 1986;164(1):251–262.
   PubMed Web of Science ®Google Scholar
• Approval Package for Application Number 103362Org1S5240. Leukine for injection, subcutaneous or intravenous use; a new indication to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation. Syndrome of Acute Radiation Syndrome 2018 Mar 29.
   Google Scholar
• Zhong Y, Pouliot M, Downey AM, et al. Efficacy of delayed administration of sargramostim up to 120 hours post exposure in a nonhuman primate total body radiation model. Int J Radiat Biol. 2021;97(sup1):S100–S116.
   Web of Science ®Google Scholar
• Clayton NP, Khan-Malek RC, Dangler CA, et al. Sargramostim (rhu GM-CSF) improves survival of non-human primates with severe bone marrow suppression after acute, high-dose, whole-body irradiation. Radiat Res. 2021;195(2):191–199.
   PubMed Web of Science ®Google Scholar
• Doyle-Eisele M Final study report study 14-045, Lovelace Biomedical Research Institute (2014).
   Google Scholar
• Gluzman-Poltorak Z, Vainstein V, Basile LA. Association of hematological nadirs and survival in a nonhuman primate model of hematopoietic syndrome of acute radiation syndrome. Radiat Res. 2015;184(2):226–230.
   PubMed Web of Science ®Google Scholar
• Farese AM, Bennett AW, Gibbs A, et al. Efficacy of Neulasta or Neupogen on H-ARS and GI-ARS mortality and hematopoietic recovery in nonhuman primates after 10-Gy irradiation with 2.5% bone marrow sparing. Health Phys. 2019;116(3):339–353.
   PubMed Web of Science ®Google Scholar
• Farese AM, Brown CR, Smith CP, et al. The ability of filgrastim to mitigate mortality following LD50/60 total-body irradiation is administration time-dependent. Health Phys. 2014;106(1):39–47.
   PubMed Web of Science ®Google Scholar
• Farese AM, Cohen MV, Katz BP, et al. Filgrastim improves survival in lethally irradiated nonhuman primates. Radiat Res. 2013;179(1):89–100.
   PubMed Web of Science ®Google Scholar
• Hankey KG, Farese AM, Blaauw EC, et al. Pegfilgrastim improves survival of lethally irradiated nonhuman primates. Radiat Res. 2015;183(6):643–655.
   PubMed Web of Science ®Google Scholar
• NPlate® (romniplostom). Full prescribing information. Amgen Inc.; Thousand Oaks: CA: 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125268s167lbl.pdf
   Google Scholar
• RdeL M, Skelly RR, Taylor P, et al. Recovery from severe hematopoietic suppression using recombinant human granulocyte-macrophage colony-stimulating factor. Exp. Hematol. 1988;16. 346–348.
   Web of Science ®Google Scholar
• Approval of Biological Products When Human Efficacy Studies Are Not Ethical or Feasible, 21 CFR 601.90-95. Cited May/19/2022 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=601.90
   Google Scholar
• Lazarus HM, Armitage JO, Gale RP. Role of molecularly-cloned hematopoietic growth factors after acute high-dose radiation exposures. J Radiol Prot. 2021;41(4):S478–S489.
   Web of Science ®Google Scholar
• Singh VK, Seed TM. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures. Int J Radiat Biol. 2017;93(9):851–869.
   PubMed Web of Science ®Google Scholar
• Yeddanapudi N, Clay MA, Durham DP, et al. Informing CONOPS and medical countermeasure deployment strategies after an improvised nuclear device detonation: the importance of delayed treatment efficacy data. Int J Radiat Biol. 2020;96(1):4–11.
   PubMed Web of Science ®Google Scholar
• https://www.phe.gov/about/sns/Pages/about.aspx (Cited May/22/2022).
   Google Scholar
• https://www.fda.gov/drugs/nda-and-bla-approvals/animal-rule-approvals ( Cited 5/22/22).
   Google Scholar
• National Academies of Sciences, Engineering, and Medicine 2019. Exploring Medical and Public Health Preparedness for a Nuclear Incident: Proceedings of a Workshop. Washington, DC. The National Academies Press. 10.17226/25372.
   Google Scholar
• Gale RP, Butturini A. Medical response to nuclear and radiation accidents. Occup Med. 1991;6(4):581–596.
   PubMedGoogle Scholar
• United Nations Scientific Committee on the Effects of Atomic Radiation. The Chernobyl accident. UNSCEAR’s assessments of the radiation effects. https://www.unscear.org/unscear/en/chernobyl.html (Cited May/22/2022).
   Google Scholar
• Gale RP, Vorobiov A. First use of myeloid colony-stimulating factors in humans. Bone Marrow Transplant. 2013;48(10):1358.
   PubMed Web of Science ®Google Scholar
• Gusev I, Guskova A, Mettler FA, editors. Medical management of radiation accidents. 2nd. CRC Press. 2001.
   Google Scholar
• Butturini A, De Souza PC, Gale RP, et al. Use of recombinant granulocyte-macrophage colony stimulating factor in the Brazil radiation accident. Lancet. 1988;2(8609):471–475.
   PubMed Web of Science ®Google Scholar
• Thierry D, Gourmelon P, Parmentier C, et al. Haematopoietic growth factors in the treatment of therapeutic and accidental irradiation-induced bone marrow aplasia. Int J Radiat Biol. 1995;67(2):103–117.
   PubMed Web of Science ®Google Scholar
• The International Atomic Energy Agency (in cooperation with The Pan American Health Organization of the World Health Organization. The radiological accident in san salvador. IAEA. Vienna; 1990.
   Google Scholar
• The International Atomic Energy Agency. The radiological accident at the irradiation facility in Nesvizh. IAEA, Vienna; 1996.
   Google Scholar
• Liu Q, Jiang B, Jiang LP, et al. Clinical report of three cases of acute radiation sickness from a (60)Co radiation accident in Henan Province in China. J Radiat Res. 2008;49(1):63–69.
   PubMed Web of Science ®Google Scholar
• Barriga LE, Zaharia M, Pinillos L, et al. Long-term follow-up of radiation accident patients in Peru: review of two cases. Radiat Prot Dosimetry. 2012;151(4):652–655.
   PubMed Web of Science ®Google Scholar
• The International Atomic Energy. The radiological accident in yanango. IAEA. Vienna. 2000. https://www.iaea.org/publications/6090/the-radiological-accident-in-yanango
   Google Scholar
• The International Atomic Energy. The Radiological Accident in Samut Prakarn. IAEA. Vienna. 2002. https://www.iaea.org/publications/6375/the-radiological-accident-in-samut-prakarn
   Google Scholar
• Jinaratana V. The medical basis for radiation-accident preparedness: the clinical care of victims. In: editors, In: Ricks ME, Rickes RC, Berger ME, et al. The radiologic accident at Thailand. 1st ed. Nashville: TN: Parthenon Publishing Group; 2002.
   Google Scholar
• Lessons Learned From The JCO Nuclear Criticality Accident in Japan in 1999. https://www-ns.iaea.org/downloads/iec/tokaimura-report.pdf
   Google Scholar
• The International Atomic Energy. Report on the preliminary fact finding mission following the accident at the nuclear fuel processing facility in Tokaimura Japan. Vienna 1999. https://www-pub.iaea.org/MTCD/Publications/PDF/TOAC_web.pdf
   Google Scholar
• Hirama T, Tanosaki S, Kandatsu S, et al. Initial medical management of patients severely irradiated in the Tokai-mura criticality accident. Br J Radiol. 2003;76(904):246–253.
   PubMed Web of Science ®Google Scholar
• Guo M, Dong Z, Qiao J, et al. Severe acute radiation syndrome: treatment of a lethally 60Co-source irradiated accident victim in China with HLA-mismatched peripheral blood stem cell transplantation and mesenchymal stem cells. J Radiat Res. 2014;55(2):205–209.
   PubMed Web of Science ®Google Scholar
• le-meḥḳar Gar’ini M, Naḥal Śoreḳ (Israel). The radiological accident in Soreq. International Atomic Energy Agency. Technol Eng. 1993.
   Google Scholar
• Satyamitra MM, Perez-Horta Z, DiCarlo AL, et al. NIH policies and regulatory pathways to U.S. FDA licensure: strategies to inform advancement of radiation medical countermeasures and biodosimetry devices. Radiat Res. 2022;197(5):533–553.
   PubMed Web of Science ®Google Scholar
• Barquinero JF, Fattibene P, Chumak V, et al. Lessons from past radiation accidents: critical review of methods addressed to individual dose assessment of potentially exposed people and integration with medical assessment. Environ Int. 2021;146:106175.
   PubMed Web of Science ®Google Scholar
• Fliedner TM, Powles R, Sirohi B, European Group for Blood and Marrow Transplantation (EBMT) Nuclear Accident Committee (NAC), et al. Radiologic and nuclear events: the METREPOL severity of effect grading system. Blood. 2008;111(12):5757–5758. author reply 5758-9.
   PubMed Web of Science ®Google Scholar
• DiCarlo AL, Cassatt DR, Dowling WE, et al., Challenges and benefits of repurposing products for use during a radiation public health emergency: lessons learned from biological threats and other disease treatments. Radiat Res. 2018;190(6): 659–676.
   PubMed Web of Science ®Google Scholar
• DiCarlo AL. Scientific research and product development in the United States to address injuries from a radiation public health emergency. J Radiat Res. 2021;62(5):752–763.
   PubMed Web of Science ®Google Scholar
• Palmer JL, Deburghgraeve CR, Bird MD, et al. Development of a combined radiation and burn injury model. J Burn Care Res. 2011;32(2):317–323.
   PubMed Web of Science ®Google Scholar
• The effects of atomic bombs on Hiroshima and Nagasaki II. The effects of the atomic bombings. B. General Effects. 1. Casualties https://www.atomicarchive.com/resources/documents/bombing-survey/section_IIb1.html
   Google Scholar
• Taliaferro LP, Cassatt DR, Horta ZP, et al. Meeting report: a poly-pharmacy approach to mitigate acute radiation syndrome. Radiat Res. 2021;196(4):436–446.
   PubMed Web of Science ®Google Scholar
• DiCarlo AL, Ramakrishnan N, Hatchett RJ. Radiation combined injury: overview of NIAID research. Health Phys. 2010;98(6):863–867.
   PubMed Web of Science ®Google Scholar
• Browne D, Weiss JF, MacVittie TJ, et al. Treatment of Radiation Injuries. Proceeding of the First Consensus Development Conference on the Treatment of Radiation Injuries. Plenum Press, New York, 1990.
   Google Scholar
• MacVittie TJ, Weiss JF, Browne D Advances in the Treatment of Radiation Injuries. Proceedings of the Second Consensus Development Conference on the Treatment of Radiation Injuries. Pergamon/Elsevier. Tarrytown, NY 1996.
   Google Scholar
• Dainiak N. Medical management of acute radiation syndrome and associated infections in a high-casualty incident. J Radiat Res. 2018;59(suppl_2):ii54–ii64.
   PubMedGoogle Scholar
• Wong K, Bunin DI, Bujold K, et al. PS13-04: romiplostim (Nplate®) alone and in combination with pegfilgrastim (Neulasta®) increased survival and reduced incidence, duration, and severity of thrombocytopenia post-irradiation in nonhuman primates. In: 66th Annual Meeting of the Radiation Research Society. 2020.
   Google Scholar
• Radiation Emergency Medical Management (REMM) 2022 Guidance on diagnosis and treatment for healthcare providers available at: https://remm.hhs.gov/index.html Cited 2022 Sept 18)
   Google Scholar
• Goyal RK, McManus JL, Gopalakrishnan M Machine learning-based meta-analysis of H-ARS studies in NHPs: hematologic myeloid predictors & confirmation of Leukine® benefit across myeloid lineages. radiation injury treatment network: past informing the present, Past Improving the Plan for a Rad/Nuc Incident, 2022 Aug.
   Google Scholar